David Young Buys 124,500 Shares of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Stock

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) insider David Young bought 124,500 shares of the stock in a transaction dated Monday, January 27th. The stock was purchased at an average price of $0.80 per share, with a total value of $99,600.00. Following the acquisition, the insider now directly owns 205,405 shares in the company, valued at approximately $164,324. The trade was a 153.88 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Processa Pharmaceuticals Price Performance

Shares of PCSA opened at $0.65 on Friday. Processa Pharmaceuticals, Inc. has a 1-year low of $0.47 and a 1-year high of $3.31. The company has a 50-day moving average of $0.92 and a 200 day moving average of $1.23. The firm has a market capitalization of $2.14 million, a price-to-earnings ratio of -0.19 and a beta of 0.62.

Processa Pharmaceuticals (NASDAQ:PCSA) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.03). On average, equities analysts anticipate that Processa Pharmaceuticals, Inc. will post -4.05 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Processa Pharmaceuticals in a report on Thursday, December 5th.

Processa Pharmaceuticals Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.